![]() |
市場調查報告書
移植物抗宿主病 (GvHD):亞太地區的流行病學的預測 (到2028年)Graft-Versus-Host Disease: Epidemiology Forecast in Asia-Pacific Markets to 2028 |
||||||
出版商 | GlobalData | 商品編碼 | 929721 | ||||
出版日期 | 內容資訊 | 英文 44 Pages ![]() |
|||||
價格 |
|
移植物抗宿主病 (GvHD):亞太地區的流行病學的預測 (到2028年) Graft-Versus-Host Disease: Epidemiology Forecast in Asia-Pacific Markets to 2028 | ||
出版日期: 2020年02月28日 | 內容資訊: 英文 44 Pages |
|
亞太地區的主要5個國家 (澳洲、中國、印度、日本、韓國) 的移植物抗宿主病 (GvHD)的發病數量,2018年∼2028年之間預計從8,794件到13,673件,以年度平均 (AGR) 5.55%的速度增加。這個增加,原因之一是這5個國家的移植手術有緩慢地上升趨勢。預計還有aGvHD的發病數量從2018年的4,650案例,到2028年增加到7,212案例,cGvHD的發病數量從2018年的4,144案例,到2028年增加到6,461案例。
本報告提供亞太地區的主要5個國家 (澳洲、中國、印度、日本、韓國) 的移植物抗宿主病 (GvHD)的發病情形與今後預測相關分析,疾病的特徵和目前的發病情形,今後10年的發病數量、患病數量的預測值等調查。
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
GvHD is a common complication of allogeneic HSCT that occurs when the donated (graft) cells are rejected and attack the host's cells as foreign. GvHD can progress from mild to severe forms as either aGvHD or cGvHD. Both aGvHD and cGvHD commonly affect organs such as the skin, gastrointestinal (GI) tract, liver, oral mucosa, and eyes. The global distribution of GvHD is directly dependent on transplantation-related factors, including the donor type, the age of the donor and the recipient, the sex parity between the recipient and the donor, the pre-transplantation conditioning regimen, and the use of GvHD prophylaxis pre- and/or post-transplantation.
GlobalData epidemiologists utilized historical HSCT data available through country-wide registry reports in the 5GM to the best extent possible to arrive at a meaningful in-depth analysis and forecast for GvHD. In this analysis, GlobalData epidemiologists provided detailed, clinically relevant segmentations for the diagnosed aGvHD and cGvHD incident cases. Further, GlobalData epidemiologists used country-specific estimates using valid diagnostic criteria to present aGvHD and cGvHD prevalent, grades and mortality cases.
The following data describes epidemiology of GvHD cases. In 2018, the 5GM had 8,794 diagnosed incident cases of GvHD (aGvHD and cGvHD). This is expected to increase to 13,673 diagnosed incident cases by 2028, at an Annual Growth Rate (AGR) of 5.55%. This increase is partly attributed to the moderately rising trend in incidence in transplantation in the 5GM. In the 5GM, the diagnosed incident cases of aGvHD will increase from 4,650 cases in 2018 to 7,212 cases in 2028, at an Annual Growth Rate (AGR) of 5.51% per year, and the diagnosed incident cases of cGvHD will increase from 4,144 cases in 2018 to 6,461 cases in 2028, at an AGR of 5.59% per year.
The GvHD Epidemiology series will allow you to -